Pharma's Market
SPECIAL REPORT
MOST SHARED
- Marc Faber: 100% Chance of Global Recession
- Time for Flash Sales to Adapt or Die
- How to Trade on the Jobs Report
- Citigroup Lost $20 Million on Facebook IPO Trades
- Don’t Trust Buybacks
- Buy Broken Stocks, Not Broken Companies
- The Biggest Market Myth There Is?
- Facebook: The Song — Yes, We're Serious
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Buying the Right Sell-Off Stocks
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- Sticker Shock: What College Is Likely to Cost in 18 Years
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- Icahn Raises Stake in Chesapeake, Wants Board Seats
- Marc Faber: Chance of Global Recession Is Now 100%
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- What Happened to Stocks? Most Unloved in 50 Years
- Cool Jobs: From Gold Stacker to Bed Tester
- Many Greeks Moved Their Money Abroad Long Ago
RSS FEED
Medivation's Presentation
Text Size 
Reporter
 |
MDVN[MDV
Loading...
()
] CEO Dr. David Hung did the honors before a crowd of around 100. It was not standing room only, but close. (Some investors measure Wall Street interest in a company/stock by attendance at events like this.)
Dr. Hung already had a colorful, fully-produced PowerPoint slide detailing the deal toward the top of his presentation. One column was titled "Pfizer Powerhouse", referring to the company's Alzheimer's drug know-how and its wide-reaching sales force.
Most of the stuff in his formal remarks was rehash, but in the breakout session that followed (that's where attendees throw questions at executives from presenting companies) a MDVN exec provided an interesting peak behind the corporate due diligence curtain.
He said that PFE [PFE
Loading...
()
]had a team of 25 people looking at the drug for about six months. The vetting, he said, "was as thorough as it gets." PFE even sent people to Russia where Alzheimer's tests were being done because the drug, called Dimebon, is an old antihistamine in that country.
Dr. Hung said he likes "to discover diamonds in the rough" like Dimebon and that it took him about two years to find it. "We probably say 'no' to more than 99 percent of (the drugs) we see," he said.
The breakout session, by the way, was standing room only.
And a disclosure: GE [GE
Loading...
()
] Healthcare, part of CNBC's parent company, is one of the sponsors of this conference.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
